ID   LPXC_ECOLI              Reviewed;         305 AA.
AC   P0A725; P07652;
DT   01-APR-1988, integrated into UniProtKB/Swiss-Prot.
DT   07-JUN-2005, sequence version 1.
DT   15-MAR-2017, entry version 96.
DE   RecName: Full=UDP-3-O-acyl-N-acetylglucosamine deacetylase {ECO:0000255|HAMAP-Rule:MF_00388, ECO:0000303|PubMed:8530464};
DE            Short=UDP-3-O-acyl-GlcNAc deacetylase {ECO:0000255|HAMAP-Rule:MF_00388, ECO:0000303|PubMed:8530464, ECO:0000303|Ref.7};
DE            EC=3.5.1.108 {ECO:0000255|HAMAP-Rule:MF_00388, ECO:0000269|PubMed:10026271, ECO:0000269|PubMed:11148046, ECO:0000269|PubMed:15705580, ECO:0000269|PubMed:8530464, ECO:0000269|PubMed:8824222};
DE   AltName: Full=Protein EnvA {ECO:0000305};
DE   AltName: Full=UDP-3-O-[R-3-hydroxymyristoyl]-N-acetylglucosamine deacetylase {ECO:0000255|HAMAP-Rule:MF_00388, ECO:0000303|PubMed:8824222};
GN   Name=lpxC {ECO:0000255|HAMAP-Rule:MF_00388,
GN   ECO:0000303|PubMed:8530464};
GN   Synonyms=asmB {ECO:0000303|PubMed:8752330},
GN   envA {ECO:0000303|PubMed:3000876}; OrderedLocusNames=b0096, JW0094;
OS   Escherichia coli (strain K12).
OC   Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacterales;
OC   Enterobacteriaceae; Escherichia.
OX   NCBI_TaxID=83333;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=K12;
RX   PubMed=2824434; DOI=10.1128/jb.169.12.5408-5415.1987;
RA   Beall B., Lutkenhaus J.;
RT   "Sequence analysis, transcriptional organization, and insertional
RT   mutagenesis of the envA gene of Escherichia coli.";
RL   J. Bacteriol. 169:5408-5415(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12;
RX   PubMed=1630901; DOI=10.1093/nar/20.13.3305;
RA   Yura T., Mori H., Nagai H., Nagata T., Ishihama A., Fujita N.,
RA   Isono K., Mizobuchi K., Nakata A.;
RT   "Systematic sequencing of the Escherichia coli genome: analysis of the
RT   0-2.4 min region.";
RL   Nucleic Acids Res. 20:3305-3308(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   PubMed=9278503; DOI=10.1126/science.277.5331.1453;
RA   Blattner F.R., Plunkett G. III, Bloch C.A., Perna N.T., Burland V.,
RA   Riley M., Collado-Vides J., Glasner J.D., Rode C.K., Mayhew G.F.,
RA   Gregor J., Davis N.W., Kirkpatrick H.A., Goeden M.A., Rose D.J.,
RA   Mau B., Shao Y.;
RT   "The complete genome sequence of Escherichia coli K-12.";
RL   Science 277:1453-1462(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911;
RX   PubMed=16738553; DOI=10.1038/msb4100049;
RA   Hayashi K., Morooka N., Yamamoto Y., Fujita K., Isono K., Choi S.,
RA   Ohtsubo E., Baba T., Wanner B.L., Mori H., Horiuchi T.;
RT   "Highly accurate genome sequences of Escherichia coli K-12 strains
RT   MG1655 and W3110.";
RL   Mol. Syst. Biol. 2:E1-E5(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-82.
RC   STRAIN=K12;
RX   PubMed=3000876; DOI=10.1016/0378-1119(85)90179-9;
RA   Yi Q.-M., Lutkenhaus J.;
RT   "The nucleotide sequence of the essential cell-division gene ftsZ of
RT   Escherichia coli.";
RL   Gene 36:241-247(1985).
RN   [6]
RP   PROTEIN SEQUENCE OF 1-19, FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY.
RX   PubMed=8530464; DOI=10.1074/jbc.270.51.30384;
RA   Young K., Silver L.L., Bramhill D., Cameron P., Eveland S.S.,
RA   Raetz C.R., Hyland S.A., Anderson M.S.;
RT   "The envA permeability/cell division gene of Escherichia coli encodes
RT   the second enzyme of lipid A biosynthesis. UDP-3-O-(R-3-
RT   hydroxymyristoyl)-N-acetylglucosamine deacetylase.";
RL   J. Biol. Chem. 270:30384-30391(1995).
RN   [7]
RP   FUNCTION.
RA   Young K., Silver L.L., Bramhill D., Caceres C.A., Stachula S.A.,
RA   Shelly S.E., Raetz C.R.H., Anderson M.S.;
RT   "The second step of lipid A biosynthesis, UDP-3-O-acyl-GlcNAc
RT   deacetylase is encoded by the pleotropic permeability/cell division
RT   gene envA of E.coli.";
RL   FASEB J. 7:1268-1268(1993).
RN   [8]
RP   VARIANTS.
RX   PubMed=8752330; DOI=10.1128/jb.178.17.5138-5143.1996;
RA   Kloser A.W., Laird M.W., Misra R.;
RT   "asmB, a suppressor locus for assembly-defective OmpF mutants of
RT   Escherichia coli, is allelic to envA (lpxC).";
RL   J. Bacteriol. 178:5138-5143(1996).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, AND ENZYME REGULATION.
RC   STRAIN=K12;
RX   PubMed=8824222; DOI=10.1074/jbc.271.42.25898;
RA   Sorensen P.G., Lutkenhaus J., Young K., Eveland S.S., Anderson M.S.,
RA   Raetz C.R.;
RT   "Regulation of UDP-3-O-[R-3-hydroxymyristoyl]-N-acetylglucosamine
RT   deacetylase in Escherichia coli. The second enzymatic step of lipid a
RT   biosynthesis.";
RL   J. Biol. Chem. 271:25898-25905(1996).
RN   [10]
RP   FUNCTION, CATALYTIC ACTIVITY, COFACTOR, ENZYME REGULATION, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=10026271; DOI=10.1021/bi982339s;
RA   Jackman J.E., Raetz C.R., Fierke C.A.;
RT   "UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase of
RT   Escherichia coli is a zinc metalloenzyme.";
RL   Biochemistry 38:1902-1911(1999).
RN   [11]
RP   DEGRADATION BY FTSH PROTEASE, AND ENZYME REGULATION.
RC   STRAIN=K12 / W3110, and W2252;
RX   PubMed=10048027; DOI=10.1046/j.1365-2958.1999.01221.x;
RA   Ogura T., Inoue K., Tatsuta T., Suzaki T., Karata K., Young K.,
RA   Su L.H., Fierke C.A., Jackman J.E., Raetz C.R., Coleman J.,
RA   Tomoyasu T., Matsuzawa H.;
RT   "Balanced biosynthesis of major membrane components through regulated
RT   degradation of the committed enzyme of lipid A biosynthesis by the AAA
RT   protease FtsH (HflB) in Escherichia coli.";
RL   Mol. Microbiol. 31:833-844(1999).
RN   [12]
RP   CATALYTIC ACTIVITY, AND MUTAGENESIS OF HIS-19; GLU-78; HIS-79;
RP   HIS-238; ASP-242; ASP-246 AND HIS-265.
RX   PubMed=11148046; DOI=10.1021/bi001872g;
RA   Jackman J.E., Raetz C.R., Fierke C.A.;
RT   "Site-directed mutagenesis of the bacterial metalloamidase UDP-(3-O-
RT   acyl)-N-acetylglucosamine deacetylase (LpxC). Identification of the
RT   zinc binding site.";
RL   Biochemistry 40:514-523(2001).
RN   [13]
RP   CATALYTIC ACTIVITY, AND ACTIVE SITE.
RX   PubMed=15705580; DOI=10.1074/jbc.M413560200;
RA   Hernick M., Gennadios H.A., Whittington D.A., Rusche K.M.,
RA   Christianson D.W., Fierke C.A.;
RT   "UDP-3-O-((R)-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase
RT   functions through a general acid-base catalyst pair mechanism.";
RL   J. Biol. Chem. 280:16969-16978(2005).
RN   [14]
RP   DEGRADATION BY FTSH PROTEASE, ENZYME REGULATION, AND DOMAIN.
RC   STRAIN=K12;
RX   PubMed=16420369; DOI=10.1111/j.1365-2958.2005.04994.x;
RA   Fuehrer F., Langklotz S., Narberhaus F.;
RT   "The C-terminal end of LpxC is required for degradation by the FtsH
RT   protease.";
RL   Mol. Microbiol. 59:1025-1036(2006).
RN   [15]
RP   DRUG TARGET.
RX   PubMed=18289052; DOI=10.2174/138920108783497668;
RA   Barb A.W., Zhou P.;
RT   "Mechanism and inhibition of LpxC: an essential zinc-dependent
RT   deacetylase of bacterial lipid A synthesis.";
RL   Curr. Pharm. Biotechnol. 9:9-15(2008).
RN   [16]
RP   COFACTOR, AND MUTAGENESIS OF CYS-63.
RX   PubMed=20136146; DOI=10.1021/bi902066t;
RA   Hernick M., Gattis S.G., Penner-Hahn J.E., Fierke C.A.;
RT   "Activation of Escherichia coli UDP-3-O-[(R)-3-hydroxymyristoyl]-N-
RT   acetylglucosamine deacetylase by Fe2+ yields a more efficient enzyme
RT   with altered ligand affinity.";
RL   Biochemistry 49:2246-2255(2010).
RN   [17]
RP   COFACTOR.
RX   PubMed=20709752; DOI=10.1074/jbc.M110.147173;
RA   Gattis S.G., Hernick M., Fierke C.A.;
RT   "Active site metal ion in UDP-3-O-((R)-3-hydroxymyristoyl)-N-
RT   acetylglucosamine deacetylase (LpxC) switches between Fe(II) and
RT   Zn(II) depending on cellular conditions.";
RL   J. Biol. Chem. 285:33788-33796(2010).
RN   [18]
RP   DRUG TARGET.
RX   PubMed=20019290; DOI=10.1177/1087057109355319;
RA   Langsdorf E.F., Malikzay A., Lamarr W.A., Daubaras D., Kravec C.,
RA   Zhang R., Hart R., Monsma F., Black T., Ozbal C.C., Miesel L.,
RA   Lunn C.A.;
RT   "Screening for antibacterial inhibitors of the UDP-3-O-(R-3-
RT   hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) using a high-
RT   throughput mass spectrometry assay.";
RL   J. Biomol. Screen. 15:52-61(2010).
RN   [19]
RP   DEGRADATION BY FTSH PROTEASE, AND ENZYME REGULATION.
RX   PubMed=21193611; DOI=10.1128/JB.01043-10;
RA   Langklotz S., Schaekermann M., Narberhaus F.;
RT   "Control of lipopolysaccharide biosynthesis by FtsH-mediated
RT   proteolysis of LpxC is conserved in enterobacteria but not in all
RT   gram-negative bacteria.";
RL   J. Bacteriol. 193:1090-1097(2011).
RN   [20]
RP   DEGRADATION BY FTSH PROTEASE, AND ENZYME REGULATION.
RX   PubMed=23417489; DOI=10.1128/JB.02134-12;
RA   Schaekermann M., Langklotz S., Narberhaus F.;
RT   "FtsH-mediated coordination of lipopolysaccharide biosynthesis in
RT   Escherichia coli correlates with the growth rate and the alarmone
RT   (p)ppGpp.";
RL   J. Bacteriol. 195:1912-1919(2013).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.59 ANGSTROMS) IN COMPLEX WITH
RP   UDP-(3-O-(R-HYDROXYMYRISTOYL))-GLUCOSAMINE AND ZINC, AND ACTIVE SITE.
RX   PubMed=24108127; DOI=10.1074/jbc.M113.513028;
RA   Clayton G.M., Klein D.J., Rickert K.W., Patel S.B., Kornienko M.,
RA   Zugay-Murphy J., Reid J.C., Tummala S., Sharma S., Singh S.B.,
RA   Miesel L., Lumb K.J., Soisson S.M.;
RT   "Structure of the bacterial deacetylase LpxC bound to the nucleotide
RT   reaction product reveals mechanisms of oxyanion stabilization and
RT   proton transfer.";
RL   J. Biol. Chem. 288:34073-34080(2013).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) IN COMPLEX WITH INHIBITORS AND
RP   ZINC.
RX   PubMed=24117400; DOI=10.1021/cb400067g;
RA   Lee C.J., Liang X., Gopalaswamy R., Najeeb J., Ark E.D., Toone E.J.,
RA   Zhou P.;
RT   "Structural basis of the promiscuous inhibitor susceptibility of
RT   Escherichia coli LpxC.";
RL   ACS Chem. Biol. 9:237-246(2014).
CC   -!- FUNCTION: Catalyzes the hydrolysis of UDP-3-O-myristoyl-N-
CC       acetylglucosamine to form UDP-3-O-myristoylglucosamine and
CC       acetate, the committed step in lipid A biosynthesis.
CC       {ECO:0000255|HAMAP-Rule:MF_00388, ECO:0000269|PubMed:10026271,
CC       ECO:0000269|PubMed:8530464, ECO:0000269|PubMed:8824222,
CC       ECO:0000269|Ref.7}.
CC   -!- CATALYTIC ACTIVITY: UDP-3-O-((3R)-3-hydroxytetradecanoyl)-N-
CC       acetyl-alpha-D-glucosamine + H(2)O = UDP-3-O-((3R)-3-
CC       hydroxytetradecanoyl)-alpha-D-glucosamine + acetate.
CC       {ECO:0000255|HAMAP-Rule:MF_00388, ECO:0000269|PubMed:10026271,
CC       ECO:0000269|PubMed:11148046, ECO:0000269|PubMed:15705580,
CC       ECO:0000269|PubMed:8530464, ECO:0000269|PubMed:8824222}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000255|HAMAP-Rule:MF_00388,
CC         ECO:0000269|PubMed:10026271, ECO:0000269|PubMed:20709752};
CC       Name=Fe(2+); Xref=ChEBI:CHEBI:29033;
CC         Evidence={ECO:0000269|PubMed:20136146,
CC         ECO:0000269|PubMed:20709752};
CC       Note=Can use either Fe(2+) or Zn(2+). The metal cofactor can
CC       switch between Fe(2+) and Zn(2+) in response to metal
CC       availability. Metal switching may be important for regulating the
CC       LpxC activity upon changes in environmental conditions. Has a
CC       significantly higher affinity for Zn(2+), but exhibits higher
CC       activity with Fe(2+) (PubMed:20136146, PubMed:20709752). Can also
CC       use Co(2+), Ni(2+) and, to a lesser extent, Mn(2+)
CC       (PubMed:10026271). {ECO:0000269|PubMed:10026271,
CC       ECO:0000269|PubMed:20136146, ECO:0000269|PubMed:20709752};
CC   -!- ENZYME REGULATION: Regulation occurs at the protein level, via
CC       degradation of LpxC by the FtsH protease (PubMed:10048027,
CC       PubMed:16420369, PubMed:21193611, PubMed:23417489). Degradation is
CC       growth rate-dependent. LpxC is degraded rapidly during slow
CC       growth, probably to avoid toxic overproduction of
CC       lipopolysaccharides, but is highly stable under optimal growth
CC       conditions (PubMed:23417489). Increased amounts of LpxC are made
CC       under conditions that reduce the lipid A content of cells
CC       (PubMed:8824222). Inhibited by metal chelators such as EDTA and
CC       dipicolinic acid (DPA) and by high concentrations of Zn(2+)
CC       (PubMed:10026271). {ECO:0000269|PubMed:10026271,
CC       ECO:0000269|PubMed:10048027, ECO:0000269|PubMed:16420369,
CC       ECO:0000269|PubMed:21193611, ECO:0000269|PubMed:23417489,
CC       ECO:0000269|PubMed:8824222}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=2.1 uM for UDP-3-O-myristoyl-N-acetylglucosamine (at 30
CC         degrees Celsius) {ECO:0000269|PubMed:10026271};
CC         KM=0.6 uM for UDP-3-O-myristoyl-N-acetylglucosamine (at 1 degree
CC         Celsius) {ECO:0000269|PubMed:10026271};
CC         Note=kcat is 3.3 sec(-1) at 30 degrees Celsius. kcat is 0.09
CC         sec(-1) at 1 degree Celsius. {ECO:0000269|PubMed:10026271};
CC   -!- PATHWAY: Glycolipid biosynthesis; lipid IV(A) biosynthesis; lipid
CC       IV(A) from (3R)-3-hydroxytetradecanoyl-[acyl-carrier-protein] and
CC       UDP-N-acetyl-alpha-D-glucosamine: step 2/6. {ECO:0000255|HAMAP-
CC       Rule:MF_00388, ECO:0000269|PubMed:8530464}.
CC   -!- DOMAIN: The N-terminus is required for deacetylase activity. The
CC       C-terminus contains a signal sequence necessary for FtsH-dependent
CC       degradation. {ECO:0000269|PubMed:16420369}.
CC   -!- PTM: Degraded by FtsH. {ECO:0000269|PubMed:10048027,
CC       ECO:0000269|PubMed:16420369, ECO:0000269|PubMed:21193611,
CC       ECO:0000269|PubMed:23417489}.
CC   -!- MISCELLANEOUS: Due to its important role in lipid A synthesis,
CC       LpxC is an attractive target for the development of new
CC       antibacterial agents to treat Gram-negative infections. Many
CC       potent LpxC inhibitors with a variety of chemical scaffolds and
CC       distinct antibiotic profiles have been discovered.
CC       {ECO:0000269|PubMed:18289052, ECO:0000269|PubMed:20019290,
CC       ECO:0000269|PubMed:24117400}.
CC   -!- SIMILARITY: Belongs to the LpxC family. {ECO:0000255|HAMAP-
CC       Rule:MF_00388}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M19211; AAA83849.1; -; Genomic_DNA.
DR   EMBL; X55034; CAA38873.1; -; Genomic_DNA.
DR   EMBL; U00096; AAC73207.1; -; Genomic_DNA.
DR   EMBL; AP009048; BAB96664.1; -; Genomic_DNA.
DR   PIR; A28381; BVECEA.
DR   RefSeq; NP_414638.1; NC_000913.3.
DR   RefSeq; WP_000595482.1; NZ_LN832404.1.
DR   PDB; 4IS9; X-ray; 2.13 A; A/B=1-300.
DR   PDB; 4ISA; X-ray; 1.80 A; A=1-300.
DR   PDB; 4MDT; X-ray; 2.59 A; A/B/C/D=1-305.
DR   PDB; 4MQY; X-ray; 2.00 A; A=1-305.
DR   PDBsum; 4IS9; -.
DR   PDBsum; 4ISA; -.
DR   PDBsum; 4MDT; -.
DR   PDBsum; 4MQY; -.
DR   ProteinModelPortal; P0A725; -.
DR   SMR; P0A725; -.
DR   BioGrid; 4261858; 357.
DR   DIP; DIP-48045N; -.
DR   IntAct; P0A725; 5.
DR   MINT; MINT-1309717; -.
DR   STRING; 511145.b0096; -.
DR   BindingDB; P0A725; -.
DR   ChEMBL; CHEMBL5244; -.
DR   PaxDb; P0A725; -.
DR   PRIDE; P0A725; -.
DR   EnsemblBacteria; AAC73207; AAC73207; b0096.
DR   EnsemblBacteria; BAB96664; BAB96664; BAB96664.
DR   GeneID; 944816; -.
DR   KEGG; ecj:JW0094; -.
DR   KEGG; eco:b0096; -.
DR   PATRIC; 32115297; VBIEscCol129921_0100.
DR   EchoBASE; EB0261; -.
DR   EcoGene; EG10265; lpxC.
DR   eggNOG; ENOG4105C7C; Bacteria.
DR   eggNOG; COG0774; LUCA.
DR   HOGENOM; HOG000256663; -.
DR   InParanoid; P0A725; -.
DR   KO; K02535; -.
DR   OMA; NSMLVKA; -.
DR   PhylomeDB; P0A725; -.
DR   BioCyc; EcoCyc:UDPACYLGLCNACDEACETYL-MONOMER; -.
DR   BioCyc; MetaCyc:UDPACYLGLCNACDEACETYL-MONOMER; -.
DR   UniPathway; UPA00359; UER00478.
DR   PRO; PR:P0A725; -.
DR   Proteomes; UP000000318; Chromosome.
DR   Proteomes; UP000000625; Chromosome.
DR   GO; GO:0005737; C:cytoplasm; IDA:EcoCyc.
DR   GO; GO:0019213; F:deacetylase activity; IDA:EcoliWiki.
DR   GO; GO:0005506; F:iron ion binding; IDA:EcoCyc.
DR   GO; GO:0008759; F:UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase activity; IDA:EcoCyc.
DR   GO; GO:0103117; F:UDP-3-O-acyl-N-acetylglucosamine deacetylase activity; IEA:UniProtKB-EC.
DR   GO; GO:0008270; F:zinc ion binding; IDA:EcoCyc.
DR   GO; GO:0009245; P:lipid A biosynthetic process; IMP:EcoliWiki.
DR   Gene3D; 3.30.1700.10; -; 1.
DR   Gene3D; 3.30.230.20; -; 1.
DR   HAMAP; MF_00388; LpxC; 1.
DR   InterPro; IPR020568; Ribosomal_S5_D2-typ_fold.
DR   InterPro; IPR004463; UDP-acyl_GlcNac_deAcase.
DR   InterPro; IPR011334; UDP-acyl_GlcNac_deAcase_C.
DR   InterPro; IPR015870; UDP-acyl_N-AcGlcN_deAcase_N.
DR   PANTHER; PTHR33694:SF2; PTHR33694:SF2; 1.
DR   Pfam; PF03331; LpxC; 1.
DR   SUPFAM; SSF54211; SSF54211; 2.
DR   TIGRFAMs; TIGR00325; lpxC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Direct protein sequencing; Hydrolase;
KW   Iron; Lipid A biosynthesis; Lipid biosynthesis; Lipid metabolism;
KW   Metal-binding; Reference proteome; Zinc.
FT   CHAIN         1    305       UDP-3-O-acyl-N-acetylglucosamine
FT                                deacetylase.
FT                                /FTId=PRO_0000191929.
FT   ACT_SITE    265    265       Proton donor. {ECO:0000255|HAMAP-
FT                                Rule:MF_00388,
FT                                ECO:0000305|PubMed:15705580,
FT                                ECO:0000305|PubMed:24108127}.
FT   METAL        79     79       Zinc; via tele nitrogen.
FT                                {ECO:0000255|HAMAP-Rule:MF_00388,
FT                                ECO:0000269|PubMed:24108127,
FT                                ECO:0000269|PubMed:24117400}.
FT   METAL       238    238       Zinc; via tele nitrogen.
FT                                {ECO:0000255|HAMAP-Rule:MF_00388,
FT                                ECO:0000269|PubMed:24108127,
FT                                ECO:0000269|PubMed:24117400}.
FT   METAL       242    242       Zinc. {ECO:0000255|HAMAP-Rule:MF_00388,
FT                                ECO:0000269|PubMed:24108127,
FT                                ECO:0000269|PubMed:24117400}.
FT   VARIANT      50     50       F -> S (in ASMB2/3; reduced activity).
FT                                {ECO:0000305|PubMed:8752330}.
FT   VARIANT     210    210       G -> S (in ASMB1; reduced activity).
FT                                {ECO:0000305|PubMed:8752330}.
FT   MUTAGEN      19     19       H->A: 1400-fold decrease in activity.
FT                                {ECO:0000269|PubMed:11148046}.
FT   MUTAGEN      19     19       H->Q: 90-fold decrease in activity.
FT                                {ECO:0000269|PubMed:11148046}.
FT   MUTAGEN      19     19       H->Y: 200-fold decrease in activity.
FT                                {ECO:0000269|PubMed:11148046}.
FT   MUTAGEN      63     63       C->A: Reduces level of inhibition by
FT                                metal ions.
FT                                {ECO:0000269|PubMed:20136146}.
FT   MUTAGEN      78     78       E->A: 700-fold decrease in activity.
FT                                {ECO:0000269|PubMed:11148046}.
FT   MUTAGEN      78     78       E->Q: 3000-fold decrease in activity.
FT                                {ECO:0000269|PubMed:11148046}.
FT   MUTAGEN      79     79       H->A: 2300-fold decrease in activity.
FT                                {ECO:0000269|PubMed:11148046}.
FT   MUTAGEN      79     79       H->Q: 1200-fold decrease in activity.
FT                                {ECO:0000269|PubMed:11148046}.
FT   MUTAGEN     238    238       H->A: 1100-fold decrease in activity.
FT                                {ECO:0000269|PubMed:11148046}.
FT   MUTAGEN     242    242       D->A: 10-fold decrease in activity.
FT                                {ECO:0000269|PubMed:11148046}.
FT   MUTAGEN     242    242       D->Q: 2300-fold decrease in activity.
FT                                {ECO:0000269|PubMed:11148046}.
FT   MUTAGEN     246    246       D->A: 1800-fold decrease in activity.
FT                                {ECO:0000269|PubMed:11148046}.
FT   MUTAGEN     265    265       H->A: 3800-fold decrease in activity.
FT                                {ECO:0000269|PubMed:11148046}.
FT   MUTAGEN     265    265       H->Q: 5600-fold decrease in activity.
FT                                {ECO:0000269|PubMed:11148046}.
FT   STRAND        3      9       {ECO:0000244|PDB:4MQY}.
FT   STRAND       11     16       {ECO:0000244|PDB:4MQY}.
FT   TURN         18     20       {ECO:0000244|PDB:4MQY}.
FT   STRAND       22     29       {ECO:0000244|PDB:4MQY}.
FT   STRAND       37     41       {ECO:0000244|PDB:4MQY}.
FT   STRAND       43     46       {ECO:0000244|PDB:4MQY}.
FT   STRAND       48     51       {ECO:0000244|PDB:4MQY}.
FT   HELIX        54     56       {ECO:0000244|PDB:4MQY}.
FT   STRAND       61     63       {ECO:0000244|PDB:4MQY}.
FT   STRAND       65     67       {ECO:0000244|PDB:4MQY}.
FT   STRAND       73     75       {ECO:0000244|PDB:4MQY}.
FT   HELIX        78     87       {ECO:0000244|PDB:4MQY}.
FT   STRAND       91    100       {ECO:0000244|PDB:4MQY}.
FT   STRAND      106    108       {ECO:0000244|PDB:4MQY}.
FT   HELIX       109    118       {ECO:0000244|PDB:4MQY}.
FT   STRAND      120    126       {ECO:0000244|PDB:4MQY}.
FT   STRAND      129    132       {ECO:0000244|PDB:4MQY}.
FT   STRAND      136    140       {ECO:0000244|PDB:4MQY}.
FT   STRAND      143    148       {ECO:0000244|PDB:4MQY}.
FT   STRAND      151    158       {ECO:0000244|PDB:4MQY}.
FT   HELIX       168    170       {ECO:0000244|PDB:4MQY}.
FT   STRAND      171    176       {ECO:0000244|PDB:4MQY}.
FT   HELIX       179    185       {ECO:0000244|PDB:4MQY}.
FT   TURN        186    188       {ECO:0000244|PDB:4MQY}.
FT   STRAND      192    194       {ECO:0000244|PDB:4MQY}.
FT   HELIX       195    202       {ECO:0000244|PDB:4MQY}.
FT   TURN        203    205       {ECO:0000244|PDB:4MQY}.
FT   STRAND      214    218       {ECO:0000244|PDB:4MQY}.
FT   STRAND      220    223       {ECO:0000244|PDB:4MQY}.
FT   HELIX       234    247       {ECO:0000244|PDB:4MQY}.
FT   HELIX       248    250       {ECO:0000244|PDB:4MQY}.
FT   STRAND      254    262       {ECO:0000244|PDB:4MQY}.
FT   HELIX       265    277       {ECO:0000244|PDB:4MQY}.
FT   HELIX       279    281       {ECO:0000244|PDB:4MQY}.
FT   STRAND      282    285       {ECO:0000244|PDB:4MQY}.
FT   HELIX       290    292       {ECO:0000244|PDB:4MQY}.
FT   HELIX       295    297       {ECO:0000244|PDB:4MQY}.
SQ   SEQUENCE   305 AA;  33956 MW;  CA439A00813463AB CRC64;
     MIKQRTLKRI VQATGVGLHT GKKVTLTLRP APANTGVIYR RTDLNPPVDF PADAKSVRDT
     MLCTCLVNEH DVRISTVEHL NAALAGLGID NIVIEVNAPE IPIMDGSAAP FVYLLLDAGI
     DELNCAKKFV RIKETVRVED GDKWAEFKPY NGFSLDFTID FNHPAIDSSN QRYAMNFSAD
     AFMRQISRAR TFGFMRDIEY LQSRGLCLGG SFDCAIVVDD YRVLNEDGLR FEDEFVRHKM
     LDAIGDLFMC GHNIIGAFTA YKSGHALNNK LLQAVLAKQE AWEYVTFQDD AELPLAFKAP
     SAVLA
//
